Clinical Trials
24 trialsNCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00719173 2024-11-04
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT00588835 2020-11-30
ACE
Radboud University Medical Center
Phase 4 Terminated
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT01450826 2018-06-26
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Phase 2 Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT02550119 2017-03-28
Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
University of Southern California
Phase NA Terminated
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT01913990 2017-01-30
ER11-02
Ottawa Hospital Research Institute
Phase 4 Unknown
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT02445872 2015-12-09
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Zhejiang University
Phase 2 Unknown
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02407600 2015-04-03
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
State University of New York - Upstate Medical University
Phase 2 Unknown
NCT01017809 2015-03-18
Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer
NYU Langone Health
Phase NA Withdrawn
NCT00651755 2013-07-02
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Phase NA Completed
NCT00314743 2013-05-24
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Washington University School of Medicine
Phase EARLY_PHASE1 Completed
NCT00499668 2013-04-02
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Withdrawn
NCT01046461 2012-02-17
RAD
Hallym University Medical Center
Phase 2 Unknown
NCT00415103 2009-09-18
AMENO-2
PETHEMA Foundation
Phase 4 Completed